TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Patient-reported Treatment Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: % of Nursing Staff Who Want to Use the System Following the Trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CD34+ Cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delirium during ICU stay
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first documented AF/AFL recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Recurrent Disease
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of hand washing technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of inflammation related bacteria in faecal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of Secure Messaging
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to Use Secure Messaging in the Future
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Benefits of Using Secure Messaging
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Renal aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pulmonary aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Liver aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neurological aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vascular aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bone aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 4-month progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence rate of transitional cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: drug efficacy of a single dose of BZ drugs against STH infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-procedure pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pharmacokinetics of Multihance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of undernutrition risk as MNA < 23.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Eastern Cooperative Oncology Group (ECOG) performance status score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tibia Trabecular Volumetric Bone Mineral Density (BMD) Z-score at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Tibia Cortical Area Z-score 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Spine Volumetric BMD Z-score at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insomnia Symptom Inventory (ISI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Intraoperative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects with 20% Improvement on the Two Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parent's knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expectations of outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device posts Sensor Off message within one minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluorescence characteristics of NAD(P)H in venous blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24 h mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cesarean Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Birth-weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disability of the shoulder, elbow and hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUCt in ng·h/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax in ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Performed HPV Self-testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Responded to the Invitation for Pap Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of postoperative myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local skin irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mobilization of DTCs from bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V4-16S rRNA and ITS1 rRNA sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of genetic alterations in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with actionable mutations detected via genetic profiling of ptDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: DAS-remission achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Change Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of HemaMax
Endpoint domain: Adverse events/effects
Primary endpoint: HES expansion plasmatic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Space between occlusal rest and rest seat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Output (UO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: prognostic biomarkers in breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative ridge height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic Anterior Motion (SAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ischemia modified albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IELT from baseline to end of Home Phase Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reporting improvement according to CGIC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Longitudinal outcomes and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Post Operative Cognitive Dysfunction (POCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Admitted to the Hospital for Headache
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Number of Days of Headache-related Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants Who Visited Any Healthcare Professional (HCP)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Subjects With hSBA Titers ≥1:4 Against Meningococcal Serogroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Outer thigh circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete and overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infections grade III, IV
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of CMV reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Percent reduction in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Injection Site Pain Assessed Using Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hopkins Verbal Learning Test-Revised (HVLT-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mini Mental State Evaluation Exam (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Epworth Sleepiness Scale [ESS]
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximum Concentration (Cmax) of Evacetrapib (LY2484595)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Evacetrapib (LY2484595)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of posterior corneal surface elevation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer on gastric varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of major hemorrhagic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to next pulmonary exacerbation requiring antibiotics, hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Presence of delayed ischemic neurological deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VF Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to computerized neurocognitive rehabilitation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative in-hospital patient's narcotic requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in low back pain as assessed by Oswestry Disability Index (ODI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain as measured by Neuropathic Pain Symptom Inventory (NPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain as measured by Multidimensional pain Inventory (MPI-SCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain as measured by the Basic Pain Data Set
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occult lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Montgomery-Asberg Rating Scale for Depression (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hemoglobin A1C (A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS (visual analog scale) for pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional status walking distance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Istanbul waist pain disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area under the plasma concentration-time course profile (AUC [0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Any Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Engraftment at 4 weeks post bone marrow transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue severity by Edmonton Symptom Assessment System
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Fatigue severity by unidimensional visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Fatigue severity by Functional Assessment of Chronic Illness Therapy Fatigue Scale Version 4
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Transepidermal Water Loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Stricture development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Worst perceived pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of traveler's diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of grade 3 and 4 acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of graft rejection following ipilimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Autoimmune reaction defined as >= grade 3 dysfunction of a vital organ or the graft
Endpoint domain: Adverse events/effects
Primary endpoint: concentration of B-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: concentration of citrullin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: concentration of ornithin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days abstinent
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change From Baseline in Aortic Characteristic Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of BrainPulse recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects alive and extubated at 48 hours
Endpoint domain: Mortality/survival
Primary endpoint: Necrotising Enterocolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood Stream Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pulsatile secretion of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in physical activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Excessive gestational weight gain (EGWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Participants That Successfully Used the iThermonitor
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Post-operative alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia)
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Probability of Resolution of Nonadherence Within 30 Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of Nonadherence Event
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: % patients >1 h of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scale calibration of the new developed questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Construct validity of the new developed questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reproductibility of the new developed questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Sitting Trough Systolic Blood Pressure (SiSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Experience an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Study Drug Discontinued Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pre dose Forced Expiratory Volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: UCLA Activity Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hip dysfunction and Osteoarthritis Outcome Score (HOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of oral cancer screening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of fungal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum concentration (Cmax) of CSL324 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 extrapolated to time infinity (AUC0-inf) of CSL324 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) of CSL324 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carriage of Vaccine Type pneumococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: TTHGR (Total Time to Hospitalization for Gastrointestinal Reasons)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of de-saturation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen saturation time < 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate Concentration in Nausea-associated Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gama-aminobutyric Acid (GABA) Concentration in Nausea-associated Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response as per CDAI (70 points)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of epidural infusion adjustments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recovery of recurrent urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Participants With Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Qualitative assessment of side-effects of chemotherapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in muscle sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Esophageal injury or erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: response rate (confirmed complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in SLE disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of HR PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough severity visual analog
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes